Indivior PLC (INDV) Stock Forecast & Price Target

Indivior PLC has demonstrated robust growth, with the number of patients receiving Sublocade treatment increasing by approximately 8% year-over-year to around 171,500 in the third quarter of 2025. The company also reported a significant rise in prescribers, reaching about 8,568, which marks an 11% increase compared to the prior year, further indicating strong market interest and acceptance of its products. Additionally, management raised its revenue guidance for Sublocade sales to a range of $825 million to $845 million, reflecting a confident outlook and an anticipated annual growth of around 10% at the midpoint, underscoring Indivior's strong positioning within the addiction treatment market.

Indivior PLC faces significant headwinds as revenue from its key product, Suboxone, is projected to decline due to increasing generic competition, which raises concerns about the company's long-term revenue stability. Although growth from Sublocade is anticipated, it is still in the early stages of its commercial lifecycle, and any potential uplift may not sufficiently counterbalance the downward trajectory of Suboxone’s revenue. Additionally, projected selling, general and administrative (SG&A) expenses remain high, estimated at approximately 45% of revenue by 2026, indicating concerns regarding profitability amidst potential revenue challenges.